Engaged in molecular diagnostics business for research into, and the development and commercialisation of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease.
12-Oct-2018 – 8.25p – £31.9m – PER n/a
Trading Update For The 6 Months To End September 2018 – Revenues up 45% with a strong start to the second half of the year. Legal issue now settled and behind them, now focused on driving global growth.
Covering this stock for the first time because it popped up on my Tech Screen a month or so ago. This is a Loss maker that is not currently forecast to make a Profit (even on forecast double the Revenue seen in 2018A) so for this reason alone it has to go straight on my Avoid list for now.